Immuron Limited · ASX:IMC
Immuron — Emerging Growth Conference February 2025
16 slides from Immuron's conference presentation, Feb 19, 2025
Slide 1: Immuron CEO presentation to Emerging Growth Conference
Immuron CEO, Steven Lydeamore presentation to Emerging Growth Conference Melbourne, Australia, February 19, 2025: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore presented virtually at the Emerging Growth Conference on Tuesday 18th February
Slide 2: For personal use only
are orally active. Bovine IgG can withstand the acidic environment of the stomach and is resistant to proteolysis by the digestive enzymes found in the Gastrointestinal (GI) tract. Bovine IgG also possesses this unique ability to remain active in the human GI tract delivering its full benefits direc
Slide 3: References
References Connor P, Porter CK, Swierczewski B and Riddle MS. Diarrhea during military deployment: current concepts and future directions. Curr Opin Infect Dis. 25(5): 546-54; 2012. Hutton, M.L., Cunningham, B.A., Mackin, K.E. et al. Bovine antibodies targeting primary and recurrent Clostridium diff
Slide 4: Emerging Growth Conference February 2025
For personal use only EMERGING GROWTH CONFERENCE 18 FEBRUARY 2025 S t e v e n Ly d e a m o r e - C E O NASDAQ: IMRN ASX: IMC 1
Slide 5: Safe Harbor Statement
SAFE HARBOR STATEMENT C e r ta i n state m e n t s m a d e i n t h i s p re s e nta t i o n a re fo r wa rd - l o o k i n g state m e n t s a n d a re b a s e d o n I m m u ro n ’s c u r re nt ex p e c tat i o n s , e st i m ate s a n d p ro j e c t i o n s . Wo rd s s u c h a s For personal use onl
Slide 6: Revenue generating with strong pipeline
REVENUE GENERATING WITH STRONG PIPELINE Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases For personal use only 30 October 2024 18 February 2025 Septemb
Slide 7: Continued strong sales growth
CONTINUED STRONG SALES GROWTH For personal use only o Global sales increased by 172% in the 2024 fiscal year to a record o USA A$4.9 million compared to A$1.8 million in FY23 o FY24: a record A$1.08 million; up 67% o Half Yearly sales record in Dec 24 A$4.0 million, up 70% pcp o Half Yearly sales in
Slide 8: Expansion of Travelan distribution
EXPANSION OF TRAVELAN® DISTRIBUTION For personal use only 5
Slide 9: Consumer marketing activity driving Travelan sales growth
CONSUMER MARKETING ACTIVITY DRIVING TRAVELAN® SALES GROWTH We continue to drive awareness, For personal use only consideration and engagement o Ranging across major retailers (Australia, Canada) o In-store positioning and promotion o Retailer catalogues o Search and social media marketing o Social c
Slide 10: Strong pipeline with near term milestones
STRONG PIPELINE WITH NEAR TERM MILESTONES For personal use only 7
Slide 11: World first triple mechanism of action for CDI
WORLD FIRST TRIPLE MECHANISM OF ACTION FOR CDI IMM-529: pre-IND filed with FDA July 2024; successful pre-IND meeting Indication / Target IMM-529 will be indicated for the treatment of recurrent C. difficile For personal use only Population infection Product • Novel antibody-containing therapeutic wh
Slide 12: Immuron's clinical programs – opportunity assessment
IMMURON’S CLINICAL PROGRAMS – OPPORTUNITY ASSESSMENT › Immuron’s development of IMM-124E (hyperimmune › Infectious disease experts reacted favorably to the IMM-529 For personal use only bovine colostrum) as a prescription medication has MOA, and its unique ability to target three elements of the the
Slide 13: New project: IMM-986 targeting VRE
NEW PROJECT: IMM-986 TARGETING VRE In collaboration with Monash University, Immuron is developing IMM-986 to specifically target Vancomycin- resistant enterococci (VRE). The objective of this collaboration is to determine whether VRE-specific colostrum results in decolonisation or removal of the res
Slide 14: Travelan progresses towards Phase 3
TRAVELAN® PROGRESSES TOWARDS PHASE 3 Travelan® (IMM-124E) Phase 2 o Travelan® IND Approval – December 2022 o Study Initiation – May 2023 For personal use only o First cohort recruitment completed – July 2023 o Presentations at Military Health System Research Symposium – August 2023 o Second cohort r
Slide 15: Steven Lydeamore, Chief Executive Officer
For personal use only STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION: EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +61 438 027 172 12
Slide 16: Scientific references
Scientific references Travelan® (IMM-124E) For personal use only Travelan® has been shown to reduce both the incidence and severity of ETEC- Scandinavian Journal of Gastroenterology, 46:7-8, 862-868, DOI: 10.3109/00365521.2011.574726 induced diarrhea in up to 90% of volunteers Clinical Evaluation of